{"id":"pcra-intermittent-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCRA (Personalized Cancer Vaccine) is designed as an autologous cell-based immunotherapy that primes T-cell responses against tumor-associated antigens. Administered as intermittent injections, it aims to enhance anti-tumor immunity by activating dendritic cells and cytotoxic T lymphocytes. The exact molecular targets and antigen specificity are proprietary to Örebro University's development.","oneSentence":"PCRA is a peptide-based immunotherapeutic that stimulates the patient's own immune system to recognize and attack cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:59:55.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (marketed indication)"}]},"trialDetails":[{"nctId":"NCT01492075","phase":"PHASE4","title":"A Comparison Between Continuous and Intermittent Intraabdominal Analgesia Using Local Anaesthetics","status":"COMPLETED","sponsor":"Örebro University, Sweden","startDate":"2008-01","conditions":"Abdominal Hysterectomy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PCRA (Intermittent injection)","genericName":"PCRA (Intermittent injection)","companyName":"Örebro University, Sweden","companyId":"rebro-university-sweden","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PCRA is a peptide-based immunotherapeutic that stimulates the patient's own immune system to recognize and attack cancer cells. Used for Colorectal cancer (marketed indication).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}